Pharvaris N.V. (PHVS)

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock

Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares

Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript

Pharvaris' genetic disorder drug meets main goal in late-stage trial

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS

5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet